Genetics of Plavix responsiveness

Responsiveness to clopidogrel, sold under the brand name Plavix, is an issue for some patients who undergo anti-platelet treatment to prevent heart attack and stroke. Particularly susceptible are patients who receive the drug to prevent clotting and embolism after coronary stenting. Approximately 30 to 40 percent of people have a genetic mutation that makes them unresponsive to clopidogrel treatment. Genetic tests are available to aid in determining the potential for successful treatment

Read more about genetic testing for clopidogrel responsiveness.

No comments: